Advitech Inc.

Advitech Inc.

October 06, 2005 09:00 ET

New Potential Treatment for Inflammatory Bowel Diseases: Advitech Announces Positive Results from Preclinical Study

QUEBEC CITY, QUEBEC--(CCNMatthews - Oct. 6, 2005) - Advitech Inc. (TSX VENTURE:AVI), a Canadian biotech company, today reported significant results from a preclinical study for a potentially new treatment for inflammatory bowel diseases, such as Crohn's disease and similar autoimmune colitis.

The study, which began in early 2005, was conducted in collaboration with Patrice E. Poubelle, M.D., Ds.C., of the Centre de recherche du Centre Hospitalier de l'Universite Laval (CRCHUL), Quebec, and involved two scientifically well-recognized animal models, one representing an acute phase, while the second was representative of chronic inflammation. The objective of the study was to demonstrate that XP-828L, the Company's product for chronic inflammatory disorders, can significantly reduce clinical symptoms associated with inflammatory colitis.

The in vivo results obtained with two models have demonstrated statistically significant improvements of several clinical parameters associated with inflammatory colitis. The study has also shown a dose-dependent effect of XP-828L. Safety of the product was evaluated throughout the eight-month study, and confirmed the excellent safety profile of XP-828L at different dosages.

"This study represents a major development in the search for a safe and effective treatment option for patients suffering from IBD," stated Dr. Patrice E. Poubelle, Advitech's Scientific Advisor. "Physicians and patients are seeking new options that can provide long-term relief of this chronic condition, with easy-to-use and safe treatments. The next step is to conduct a first human clinical trial aimed at confirming the potential of this product in improving this medical condition in a safe and effective way," he added.

Renaud Beauchesne, President and CEO of Advitech, declared: "These results demonstrate the potential of our XP-828L platform in supporting the development of multiple applications for chronic inflammatory disorders. Our strategy is now to team up with the best partner possible to develop this opportunity, and bring it to market. As for psoriasis, we believe there is a significant unmet demand for an easy-to-use and safe product that can improve the quality of life of patients over the long term."

About Inflammatory Bowel Diseases (IBD)

Crohn's disease (CD) and ulcerative colitis (UC), collectively referred to as IBDs, are chronic recurrent autoimmune diseases affecting the small intestine and colon. Both CD and UC are characterized by the inflammation of various linings of the digestive tract and involve a deregulation of the body's immune system. A recent study conducted by Navigant Consulting Inc., showed that the worldwide market for IBD treatments could reach US $2.88 billion by 2009. There is no cure for IBD and there is an unmet demand for a safe and effective therapy that can maintain remission of the disease on a long-term basis.

About XP-828L

XP-828L is a patented growth factor complex used as an orally administered product for immune-mediated chronic inflammatory diseases (I.M.I.D.) such as psoriasis, as well as Crohn's disease and ulcerative colitis.

About Advitech

Advitech is a Canadian biotechnology company specializing in the development of treatments for chronic immune-mediated inflammatory diseases (I.M.I.D.). Advitech's common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 54,799,818.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Advitech Inc.
    Michel Lamontagne, MBA
    Vice-President and Chief Financial Officer
    (418) 686-7498, ext. 237
    For Media and Investors
    Echoes Financial Network Inc.
    Dominic Sicotte
    (514) 842-9551, ext. 236
    For Media and Investors
    Echoes Financial Network Inc.
    Martin Lavoie
    (514) 842-9551, ext. 231